Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central anxious method, conolidine modulates alternate molecular targets. A Science Improvements review discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://paula680smf5.wikinewspaper.com/user